July , 2009 - The collaboration project with TxCell, TcLand, INSERM U844/CHRU Montpellier, has been approuved by the French Public Institutions for the development of Tr1 cell-based technology in Rheumatoid Arthritis and Juvenile Idiopathic Arthritis. [Txcell's news]
About TxCell
Based in Sophia-Antipolis, a large business park near Nice in France, TxCell is a biotechnology company founded in 2001 which is developing new therapies to cure inflammatory and autoimmune diseases.
The natural balance between effector T cells and regulatory T cells is essential for the immune system to control autoimmunity against self or environmental antigens.
Its dysregulation leads to uncontrolled development of inflammatory and autoimmune diseases. TxCell’s strategy aims to regenerate this immunologic equilibrium by bringing type 1 T regulatory cells to the body.
Crohn’s disease, multiple sclerosis, psoriasis or rheumatoid arthritis are autoimmune chronic diseases which require alternative shock and long-term treatments. Current drug therapy for serious cases involves steroids and immunosuppressants which broadly suppress the immune response.
TxCell’s proposed therapy aims to suppress the inflammation and induce a tolerogenic environment within the inflamed tissues by a regenerative process of the immune balance.
Thus, regulatory Tr1 cells treatment is believed to act directly at the level of the cause of autoimmune disorders, the dysregulated immune regulation.
